Crescendo Biologics Ltd has entered into collaborations with two UK universities to accelerate development of its lead product for tumours expressing prostate-specific membrane antigen (PSMA). The product, CB307, is due to enter the clinic in 2020.
Separately Crescendo appointed Steward Kay, formerly of GlaxoSmithKline Plc, as its chief business officer.